155 related articles for article (PubMed ID: 22982894)
21. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
[TBL] [Abstract][Full Text] [Related]
23. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
[TBL] [Abstract][Full Text] [Related]
24. Re: Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Tutar E
Pathol Int; 2009 Apr; 59(4):274; author reply 274. PubMed ID: 19351375
[No Abstract] [Full Text] [Related]
25. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
26. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
27. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
28. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
29. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
30. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
Dejmek A; Hjerpe A
Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
32. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
Müller AM; Weichert A; Müller KM
Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
[TBL] [Abstract][Full Text] [Related]
33. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
34. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
35. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
36. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
[TBL] [Abstract][Full Text] [Related]
38. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
[TBL] [Abstract][Full Text] [Related]
39. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
40. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
Gotzos V; Vogt P; Celio MR
Pathol Res Pract; 1996 Feb; 192(2):137-47. PubMed ID: 8692714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
